Tech Company Financing Transactions
Sirtris Pharmaceuticals Funding Round
On 4/20/2006, Sirtris Pharmaceuticals received $37 million in Series C funding from Cargill Ventures, Genzyme Ventures and Polaris Partners.
Transaction Overview
Company Name
Announced On
4/20/2006
Transaction Type
Debt
Amount
$37,000,000
Round
Series C
Proceeds Purpose
Sirtris Pharmaceuticals Inc. has attracted a $37 million third round of financing to help fuel continued development of potential metabolic and neurological treatments.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
200 Technology Square 300
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Sirtris Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics that modulate sirtuins, a recently discovered family of enzymes that promotes the body's natural defense against disease. Also known as class III histone deacetylases (HDACs), sirtuins are attractive drug targets for diseases of aging, including metabolic and neurological diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christoph Westphal
Chief Operating Officer
Garen Bohlin
Vice President
Peter Elliott
VP - Finance
Paul Brannelly
VP - R & D
Michael Jirousek
Browse more venture capital transactions:
Prev: 4/19/2006: GAIN Capital Holdings venture capital transaction
Next: 4/20/2006: mFormation Technologies venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs